Predicting New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review
- PMID: 40142825
- PMCID: PMC11942920
- DOI: 10.3390/jcm14062018
Predicting New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review
Abstract
Hypertrophic cardiomyopathy (HCM) is a condition characterized by left ventricular hypertrophy, with physiopathological remodeling that predisposes patients to atrial fibrillation (AF). The electrocardiogram is a basic diagnostic tool for evaluating heart electrical activity. Key electrocardiographic features that correlate with AF onset are P-wave duration, P-wave dispersion, and electromechanical delay in left atrium (LA). Clinical markers, including age, body mass index, New York Heart Association functional class, and heart failure symptoms, are also strong predictors of AF in HCM. Risk scores have been created using multiple variables to better predict AF development. Increasing knowledge of genetic subsets in HCM and cardiovascular pathology in general has provided novel insight in this context. Structural and mechanical LA remodeling, including fibrosis, altered LA function, and changes in atrial size, further contribute to AF risk prediction. Cardiovascular magnetic resonance (CMR) and echocardiographic measures provide accurate information about atrial structure and function. Machine learning models are increasingly being utilized to refine risk prediction, incorporating a wide range of variables. This review highlights the multifaceted approach required to understand and predict AF development in HCM. Such an approach is imperative to enhance prognostic accuracy and improve the quality of life of these patients. Further research is necessary to refine patient outcomes and develop customized management strategies for HCM-associated AF.
Keywords: atrial cardiomyopathy; atrial fibrillation (AF); cardiovascular magnetic resonance (CMR); echocardiography; electrocardiogram (ECG); genetics; heart failure; hypertrophic cardiomyopathy (HCM); left atrial remodeling; machine learning.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Finocchiaro G., Sheikh N., Biagini E., Papadakis M., Maurizi N., Sinagra G., Pelliccia A., Rapezzi C., Sharma S., Olivotto I. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020;17:142–151. doi: 10.1016/j.hrthm.2019.07.019. - DOI - PubMed
-
- Ommen S.R., Ho C.Y., Asif I.M., Balaji S., Burke M.A., Day S.M., Dearani J.A., Epps K.C., Evanovich L., Ferrari V.A., et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1239–e1311. doi: 10.1161/CIR.0000000000001250. - DOI - PubMed
-
- D’Onofrio A., Marini M., Rovaris G., Zanotto G., Calvi V., Iacopino S., Biffi M., Solimene F., Della Bella P., Caravati F., et al. Prognostic significance of remotely monitored nocturnal heart rate in heart failure patients with reduced ejection fraction. Heart Rhythm. 2023;20:233–240. doi: 10.1016/j.hrthm.2022.10.018. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
